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Contracting CAG/CTG repeats using
the CRISPR-Cas9 nickase
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CAG/CTG repeat expansions cause over 13 neurological diseases that remain without a cure.
Because longer tracts cause more severe phenotypes, contracting them may provide a
therapeutic avenue. No currently known agent can speciﬁcally generate contractions. Using a
GFP-based chromosomal reporter that monitors expansions and contractions in the same cell
population, here we ﬁnd that inducing double-strand breaks within the repeat tract causes
instability in both directions. In contrast, the CRISPR-Cas9 D10A nickase induces mainly
contractions independently of single-strand break repair. Nickase-induced contractions
depend on the DNA damage response kinase ATM, whereas ATR inhibition increases both
expansions and contractions in a MSH2- and XPA-dependent manner. We propose that DNA
gaps lead to contractions and that the type of DNA damage present within the repeat tract
dictates the levels and the direction of CAG repeat instability. Our study paves the way
towards deliberate induction of CAG/CTG repeat contractions in vivo.
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epetitive DNA sequences are hotspots for genome
instability because they pose a particular challenge to the
DNA repair and replication machineries. Their mutation
often leads to disease1. For example, tracts of CAG/CTG triplets
(henceforth referred to as CAG repeats) longer than about 35
units cause at least 14 different currently incurable neurological
and neuromuscular diseases2. In addition, when CAG repeats
expand to pathological lengths, they become highly dynamic and
their length changes at high frequencies in both somatic and germ
cells throughout the lifetime of an individual3–6.
The molecular mechanisms governing CAG repeat instability
revolve around the ability of these sequences to fold into non-B-
DNA structures when exposed as single-stranded DNA7–9. These
unusual structures are mistaken for damaged DNA whether or
not they contain lesions. The subsequent repair is error-prone
due to the repetitive nature of the sequences and their structure-
forming ability3. Another non-mutually exclusive model suggests
that DNA damage within the repeat tract triggers repair, which is,
in turn, error-prone due to secondary structures formed by
these sequences5. In support of these models, several DNA repair
pathways promote the instability of expanded CAG repeats,
including mismatch repair10, double-strand break (DSB)
repair11–14, transcription-coupled nucleotide excision repair15,16,
base excision repair (BER)17,18, as well as DNA replication19. In
contrast, single-strand break (SSB) repair (SSBR)20 and signalling
via the DNA damage response (DDR)21 antagonize CAG repeat
instability. Therefore, changes in repeat length provide an
opportunity to understand the interaction and interdependence
of several different DNA repair pathways at naturally occurring
sequences.
Importantly, repeat length determines in large part the severity
of the diseases caused by expanded repeats4. It has therefore been
proposed that contracting the repeat tract would be beneﬁcial in
reducing phenotype expression. Repeat expansion, on the other
hand, would further exacerbate the disease symptoms4,22,23.
Currently, there is no treatment that speciﬁcally shrinks CAG
repeats. This is, in part, because the assays used to measure repeat
instability are tedious, slow and/or can only survey instability in
one direction. Consequently, the understanding of the
mechanism of CAG repeat instability remains poor. Elucidating
how contractions can be induced, without also provoking
expansions, is critical in designing therapeutic avenues.
Here we present a green ﬂuorescent protein (GFP)-based
chromosomal reporter assay that can monitor both CAG repeat
expansions and contractions in the same human cell population.
We combined this assay with gene-editing tools, namely zinc
ﬁnger nucleases (ZFNs) and the CRISPR-Cas9 technology.
We found that DSBs induced within the expanded repeat tract
either by the Cas9 nuclease or a ZFN led to both expansions and
contractions. Remarkably, the Cas9 D10A mutant (referred to as
the Cas9 nickase) induces instability with a marked bias towards
contractions and no detectable off-target mutations. We implicate
the DDR kinases ataxia telangiectasia mutated (ATM) and ataxia
telangiectasia and Rad3 related (ATR) in promoting contractions
and preventing instability, respectively. Moreover, it is not
dependent on the SSBR factors XRCC1 and PARylation. Cas9
nickase-induced repeat contraction appears to occur via a
pathway different from SSBR- or BER-induced instability.
We propose that DNA gaps may be the crucial mutagenic
intermediate during nickase-induced contractions. Our results
have important implications for gene editing in expanded
trinucleotide repeat diseases.
Results
A GFP-based assay to detect CAG repeat instability. We made
use of a recently described GFP-based assay capable of detecting
contractions in human cells24 (Fig. 1a). In this assay, CAG repeats
within the intron of a GFP mini-gene interfere with splicing in a
repeat length-dependent manner, with longer repeats diminishing
GFP production. Thus, GFP intensities, measured by ﬂow
cytometry, serve as a proxy for the length of the repeat tract
(Supplementary Fig. 1A,B). The reporter is present as a single
copy integrated in the genome of human HEK293 T-Rex Flp-In
cells. Its transcription is driven by a doxycycline (dox)-inducible
promoter. A second isogenic cell line, GFP(CAG)0, harbours the
same reporter at the same genomic location but is devoid of a
CAG repeat. Santillan et al.24 validated the assay by expressing a
ZFN that cuts the CAG repeat tract. This treatment increased
the number of cells with higher GFP intensities (GFPþ ) in a
reporter cell line with 89 repeats (GFP(CAG)89) by about 3.5-
folds, suggesting that the ZFN treatment induced contra-
ctions. They did not report testing for expansions.
To determine whether we could monitor expansions using this
assay, we sorted GFP and GFPþ cells from a population of
GFP(CAG)101 cells using ﬂuorescence-activated cell sorting
(FACS). We deﬁned GFP cells as those within the 1% of the
cells in the population expressing the least amount of GFP.
Similarly, GFPþ cells are the brightest 1% in the population.
From the GFP population, we isolated 19 clones with
expansions reaching up to 258 CAGs (Supplementary Fig. 1C).
Of the 12 GFPþ clones isolated, 11 had contractions, the largest
of which shrank the repeat tract down to 33 CAGs. The allele
sizes in GFP and GFPþ cells were signiﬁcantly different
(P¼ 1.0 10 5, using a Wilcoxon U-test), demonstrating that
repeat size differences can be detected with this assay. Sequencing
the region ﬂanking the CAG repeats also uncovered deletions in
ﬁve single clones with contractions (Supplementary Fig. 1D).
With the exception of one clone that contained a complex
rearrangement, the clones with deletions included 2 bp of
microhomology at the junction, suggesting that a minor CAG
repeat instability pathway is due to an error-prone alternative
end-joining mechanism, as suggested recently25. Similar results
were obtained after sorting cells from populations that were kept
in culture for 6 months with or without dox (Supplementary
Fig. 1E–H). These results demonstrate that the assay can detect
contractions as well as expansions that nearly triple the size of the
repeat tract.
DSBs induce both contractions and expansions. To determine
whether ZFN-induced expansions in addition to the contractions
reported by Santillan et al.24, we ﬁrst repeated the same
experiment. Here we deﬁned GFP and GFPþ cells as those
with GFP intensities in the brightest and dimmest 1%
after transfection with the control vector, (Supplementary
Fig. 2A—see Methods). We reproduced their results: ZFN
expression increased the frequency of GFPþ cells by 3.2-folds,
but had no effect on the number of GFP cells (Fig. 1b). While
optimizing the assay, we noted that GFP intensities increased on
the addition of dox for 72 h before reaching a steady-state level
(Supplementary Fig. 2B). This is in contrast to the 24 h previously
reported24. Increasing the time of GFP induction raised the
overall apparent average intensity of GFP and unmasked an
additional GFP cell population only in the sample transfected
with both ZFN arms (Fig. 1c). This approach revealed 2.5- and
3.9-fold increases in the proportion of GFP and GFPþ cells,
respectively, on expression of both ZFN arms compared with
transfecting an empty vector control (Fig. 1d). Expressing either
ZFN arm individually led to only small changes in GFP levels:
between 1.3- and 1.4-fold increases in the number of GFP cells
and between 0.9- and 1.5-fold for GFPþ cells (Fig. 1d).
Expressing both ZFN arms in the GFP(CAG)0 cell line had no
effect on GFP intensities (Supplementary Fig. 2C), conﬁrming
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that the presence of the repeat tract is necessary. We conﬁrmed
that GFP cells contained expansions and GFPþ cells harboured
contractions by sorting cells exposed to both ZFN arms. Of the 9
GFP clones analysed, 8 revealed an expansion (Supplementary
Fig. 2D,E). None of them contained deletions and were therefore
not GFP because they had lost the GFP reporter. Of the 13
GFPþ clones, 11 had contractions. Of those, 3 had deletions in
the ﬂanking sequences, which is similar to the ﬁndings of a
previous study constrained to measuring only contractions and
using a different ZFN26. Here again, the size of GFP and GFPþ
cells in the recovered clones were signiﬁcantly different
(P¼ 5 10 4, using a Wilcoxon U-test). These results
demonstrate that GFP and GFPþ cells accurately reﬂect the
presence of expansions and contractions, making this assay
especially well suited to detect expansions and contractions
quickly within a chromosomal environment.
To conﬁrm that DSBs within the repeat tract lead to both
expansions and contractions, we used a second type of
programmable nuclease: CRISPR-Cas9. This bacterial nuclease
is guided to virtually any sequence of interest by a guide RNA
(gRNA) molecule, where it induces blunt-ended DSBs, making it
a highly effective gene-editing tool27–29. Transfection of a vector
expressing a gRNA that targets the unrelated DMPK locus
(gDM1d) together with Cas9 did not affect GFP expression
(Fig. 1e). Similarly, expressing a gRNA containing six CTGs as
the target sequence (gCTG) alone, expressing the Cas9 nuclease
plus the gCTG in GFP(CAG)0 cells, or the gCTG together with a
catalytically inactive version of Cas9 (Cas9m4) did not change
GFP expression signiﬁcantly (Fig. 1e and Supplementary Fig. 2F).
However, expressing the Cas9 nuclease together with gCTG
resulted in a meek 1.4- and 1.5-fold induction of GFP and
GFPþ cells, respectively, compared with co-transfecting the Cas9
expression vector with the empty gRNA vector (Fig. 1e). This low
efﬁciency may reﬂect that the protospacer adjacent motif next to
the target sequence of gCTG is not the canonical NGG. We
conclude that DSBs induced within the repeat tract by a ZFN or
the Cas9 nuclease provoke nearly as many expansions as
contractions.
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Figure 1 | DSBs within CAG repeats lead to expansions and contractions. (a) GFP-based assay to detect changes in repeat length. (b) Representative
ﬂow cytometry proﬁles after expression of a ZFN in GFP(CAG)101 using the protocol from ref. 24. (c) Representative ﬂow cytometry proﬁles with increased
dox induction time uncovering an increase in GFP– cells on ZFN expression in GFP(CAG)101 cells (arrow). (d) Quantiﬁcation of the ZFN experiments in c
revealed that ZFN induces the appearance of GFP– and GFPþ cells. ZFNs are composed of two different ZFN arms, each fused to a FokI nuclease that must
dimerize to be active. ZFN 50 and ZFN 51 are individual ZFN arms24. The dashed line represents the number of cells present in gates set to include the
dimmest (GFP–) or brightest (GFPþ) 1% of the cells when a control vector, pcDNA3.1 Zeo, is transfected. Error bars are s.e.m. from 15 replicates for
experiments with both ZFN arms, 12 for the single ZFN transfections. (e) Quantiﬁcation of GFP– and GFPþ cells obtained after expression of the indicated
vectors. Dashed line: dimmest (GFP–) or brightest (GFPþ) 1% of the cells transfected with the Cas9 nuclease vector and the empty gRNA plasmid, pPN10.
The error bars are s.e.m. Number of replicates per treatment: pcDNAþ gDM1d, n¼ 3; pcDNAþ gCTG, n¼ 5; Cas9 m4þ gCTG, n¼4; Cas9þ gDM1d,
n¼ 3; Cas9þ gCTG, n¼ 7. FC, ﬂow cytometry; dox, doxycycline.
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The Cas9 nickase induces mainly CAG repeat contractions. The
use of the Cas9 enzyme allowed us to test whether the type of
DNA damage present within the repeat tract inﬂuences CAG
repeat instability. The Cas9 D10A mutant can be used with the
same gRNA to introduce DNA nicks on the strand com-
plementary to the gRNA30. DNA nicks are important
intermediates in repeat instability in vitro31,32. We therefore
asked whether inducing DNA nicks with the Cas9 nickase could
inﬂuence CAG repeat instability.
We found that expressing the Cas9 nickase together with
gCTG in GFP(CAG)101 cells increased the number of GFP cells
by 1.6-fold and GFPþ cells by 3.2-folds compared with cells
expressing only the nickase (Fig. 2a). Transfecting the Cas9
nickase with gCAG, which cuts the opposite strand compared
with gCTG, had a similar effect, leading to increases of 1.4- and
3.7-folds in GFP and GFPþ cells, respectively (Fig. 2a).
To control for potential indirect effects on GFP expression, we
expressed the Cas9 nickase along with gDM1d. This had no effect
on GFP expression (Fig. 2a). In addition, the gCTG alone did not
increase either GFP or GFPþ cells, similar to expressing the
gCTG together with the Cas9m4 mutant (Fig. 1e), suggesting that
the activity of the nickase is necessary. Increasing the number of
transfections to three in the span of 12 days further increased the
number of GFPþ cells to 6.2-folds, without a concomitant
change in GFP cells (Fig. 2b and Supplementary Fig. 2G,H;
P¼ 0.32 and 0.001 for GFP and GFPþ cells, respectively, using
a Wilcoxon U-test). The Cas9 nickase did not increase the
number of dead cells, which could skew the quantiﬁcation of
GFP and GFPþ cells (Supplementary Table 1). Also, the
difference in the number of GFPþ cells induced between the
nuclease and the nickase was not due to differences in expression
levels of the Cas9 enzyme (Supplementary Fig. 3A,B). We further
conﬁrmed that the way we quantiﬁed the data did not induce a
bias against expansions (Supplementary Fig. 3C,D). These
observations suggest that the Cas9 nickase leads to instability
with a bias towards contractions.
To conﬁrm this effect using an assay that is independent of the
GFP reporter, we isolated DNA after expressing the Cas9 nickase
and gCTG together and performed small-pool PCR (SP-PCR).
This method bypasses the inherant advantage in ampliﬁcation
efﬁciency that smaller alleles have by setting up a larger number
of reactions, each with only a few genomes as templates33. Using
samples treated according to our 12-day regimen, we could detect
larger and more frequent contractions in cells exposed to both the
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Figure 2 | The Cas9 nickase causes CAG repeat contraction. (a) Quantiﬁcation of the effect of Cas9 nickase expression in GFP(CAG)101 cells. Number of
replicates per treatment: gCTG, n¼ 37; gCAG, n¼ 3; gDM1d, n¼ 3. Quantiﬁcation of gCTG experiments also include results from Cas9 nickase expression
treated with DMSO and siRNAs against vimentin. Dashed line: dimmest (GFP–) or brightest (GFPþ) 1% of the cells transfected with the Cas9 nickase
vector and the empty gRNA plasmid. (b) Quantiﬁcation of GFP– and GFPþ cells after 5 days (1 transfection) or 12 days (3 transfections) of expressing the
Cas9 nickase along with gCTG in GFP(CAG)101 cells. Number of replicates per treatment: 5 days, n¼ 37 (same as in a); 12 days, n¼4 (*P¼0.001, using a
Wilcoxon U-test, compared with 5-day treatment). Dashed line: dimmest (GFP–) or brightest (GFPþ) 1% of the cells transfected with the Cas9 nickase
vector and the empty gRNA plasmid over the indicated period of time. (c) SP-PCR (top) and its quantiﬁcation (bottom) of DNA isolated from GFP(CAG)101
cells after Cas9 nickase expression with or without gCTG (shown: 100 pg DNA per PCR) or pPN10 (50pg DNA per PCR) for 12 days. b, no DNA blank. (d)
The ability of the Cas9 nickase to induce contractions is repeat-length dependent. Dashed line: dimmest (GFP–) or brightest (GFPþ) 1% of the cells
transfected with the Cas9 nickase vector and the empty gRNA plasmid in the indicated cell line. For each cell line the 1% threshold is determined
independently. The error bars are s.e.m. Number of replicates per treatment: GFP(CAG)270, n¼ 3; GFP(CAG)101, n¼ 37 (same as in a); GFP(CAG)42, n¼ 3;
GFP(CAG)18, n¼ 2; GFP(CAG)0, n¼ 13.
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nickase and gCTG (Fig. 2c). The number of contractions
accounted for nearly a third of the total alleles compared with
only 8% when cells were transfected with the Cas9 nickase-
expressing vector alone (Fig. 2c, Po0.0001, using a Fisher’s exact
test). On nickase expression there was also an increase in the
number of expansions, but there were fewer of them and the
changes in size were smaller than for the contractions. We
conclude that the Cas9 nickase targeted by gCAG or gCTG leads
to a marked bias towards contractions, which is in sharp contrast
to the results we obtained with the ZFN and the Cas9 nuclease.
We next examined the effect of repeat length on Cas9 nickase-
induced contractions. To do so, we used GFP(CAG)x cell lines
with repeat sizes ranging from 0 to 270 CAGs. We detected slight
increases of 1.2- to 1.6-fold in GFP cells on expression of both
the Cas9 nickase and gCTG. This effect was largely independent
of the repeat size, suggesting that this slight increase in GFP
cells seen in GFP(CAG)101 is only partly caused by changes in
repeat length (Fig. 2d). By contrast, the same treatment increased
the proportion of GFPþ cells in GFP(CAG)270 and GFP(CAG)101
cells, but not in GFP(CAG)42, GFP(CAG)18 nor GFP(CAG)0
(Fig. 2d). These observations suggest that normal-length repeats
are not prone to instability on action of the Cas9-nickase. We
further substantiated this claim by examining the extent of the
Cas9-induced changes at seven different loci in the genome
harbouring repeats of normal sizes (Supplementary Table 2). We
used nine GFPþ clones with contractions within the GFP
reporter caused by the action of the Cas9 nickase guided by
gCTG. Of the 126 alleles sequenced, we found that they all
remained mutation-free (Table 1), suggesting that the frequency
of off-target mutations caused by the nickase is low. Together,
these results argue that expanded CAG repeats are targets of the
Cas9 nickase, leading predominantly to contractions.
SSBR is not involved in Cas9 nickase-induced contractions.
Our results suggest that the type of damage induced within the
repeat tract inﬂuences instability. It was therefore important to
conﬁrm the mutagenic intermediate created by the Cas9 nickase.
The simplest hypothesis is that DNA nicks are themselves
mutagenic. We therefore tested the effect of X-Ray Repair Cross-
Complementing Protein 1 (XRCC1) and Poly (ADP-ribose)
polymerase (PARP) activities on nickase-induced instability. The
XRCC1–PARP1 complex works as a nick sensor and is involved
in their repair34. In addition, XRCC1 interacts with a number of
DNA glycosylases and is required for the repair of single-
nucleotide gaps, i.e., SSBs that arise during BER35. This is highly
relevant because BER causes expansion in a Huntington disease
mouse model17,18, and both XRCC1 and PARP1 protect against
contractions in a mammalian-based assay that is blind to
expansions20. Therefore, the prediction was that the knockdown
of XRCC1 or the inhibition of PARP using Oliparib would
signiﬁcantly affect the contraction frequencies caused by the Cas9
nickase if DNA nicks or SSBs are mutagenic. This prediction was
not conﬁrmed: neither the knockdown of XRCC1 nor the
chemical inhibition of PARP activity changed the frequency of
GFPþ cells compared with controls (Fig. 3a,b and Supplementary
Fig. 4A,B). We conﬁrmed that the XRCC1 protein levels were
substantially reduced and that the Oliparib concentration used
led to an accumulation of cells in G2 and that it inhibited
PARylation in response to Zeocin assault (Supplementary Table 3
and Fig. 3a,b). These observations suggest that the mutagenic
intermediate is neither a DNA nick nor a SSB, and imply that
nickase-induced contractions occur through a mechanism that is
distinct from spontaneous and BER-dependent CAG repeat
instability. We posit instead that DNA gaps larger than a single
nucleotide may lead to nickase-induced contractions.
ATR and ATM in Cas9 nickase-induced CAG repeat instability.
DNA gaps, for example, those induced by ultraviolet light during
G1 of the cell cycle, activate ATR36. We therefore tested the effect
of inhibiting this DDR kinase on nickase-induced instability using
the small molecule VE-821 (ref. 37). We found that this inhibitor
led to a 3.1- and 5.9-fold increase in GFP and GFPþ cells,
respectively, when used in combination with the Cas9-nickase
and gCTG (Fig. 4a, P¼ 0.03 compared with dimethylsulphoxide
(DMSO) treated cells, using a Wilcoxon U-test). This treatment
did not affect GFP expression in GFP(CAG)0 (Supplementary
Fig. 4B), conﬁrming that the effect depends on the Cas9 nickase
activity within the expanded repeat tract. These data suggest that
ATR prevents CAG repeat instability at Cas9 nickase-induced
damage.
ATM is a related DDR kinase that is partially redundant with
ATR38. Thus, we wanted to know what effect ATM might have
on nickase-induced contractions. KU60019, a speciﬁc inhibitor of
ATM39, led to a nearly two-fold reduction in the frequency of
GFPþ cells compared to DMSO-treated cells (Fig. 4a, P¼ 0.01,
using a Wilcoxon U-test). To test whether the effect of ATR was
dependent on the activity of ATM, we treated the cells with both
inhibitors simultaneously. This double treatment reduced the
number of contractions induced by the Cas9 nickase compared
with DMSO-treated cells (P¼ 0.03, using a Wilcoxon U-test), to a
level similar to using the ATM inhibitor alone (Fig. 4a, P¼ 0.57,
using a Wilcoxon U-test). These observations suggest that the
activity of ATM is required to cause nickase-induced instability in
the absence of ATR.
A role for MSH2 and XPA in the absence of ATR activity. We
next aimed to further deﬁne how the Cas9 nickase leads to a
contraction bias. A central player in CAG repeat instability is
MutS Homolog 2 (MSH2), which is essential for mismatch repair.
MSH2 knockout in mouse models and its knockdown in human
cell-based assays nearly eliminates expansions10,40,41. Its role in
Table 1 | Effect of the Cas9 nickase targeted by gCTG at CAG/CTG sites in the genome.
Locus No. of repeats* No. of alleles sequenced No. with changes
Allele 1 Allele 2
AR 20þ 5 21þ 5 18 0
ATN1 15 16 18 0
ATXN1 12þ 11 12þ 12 18 0
DMPK 5 5 18 0
PPP2R2B 10 10 18 0
TBP 9þ 18 9þ 19 18 0
TCF4 14 17 18 0
See Supplementary Table 1 for sequence composition at these loci.
*Alleles from GFPþ cells sorted from GFP(CAG)101 cells transfected with the Cas9 nickase and gCTG expressing plasmids.
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contraction, however, is more controversial. In mouse models,
knocking out MSH2 either promoted or had no effect on
contractions10. In human cells MSH2 downregulation promotes
contractions or instability in both directions, depending on the
model system used15,40,42,43. We found that MSH2 knockdown
did not consistently reduce the number of Cas9 nickase-induced
GFPþ cells compared with a control knockdown of vimentin
(Fig. 4b, P¼ 0.14, using a Wilcoxon U-test). MSH2 promotes
CAG repeat contractions together with the NER factor,
Xeroderma Pigmentosum, Complementation Group A (XPA)15,
in a human cell-based assay. XPA is also required for CAG repeat
instability in mouse neuronal tissues44 and for contractions in a
human cell-based assay15. It was therefore not surprising that the
knockdown of XPA alone or in combination with MSH2
knockdown did not signiﬁcantly reduce the frequency of
nickase-induced GFPþ cells (Fig. 4b, P¼ 0.18, using a
Wilcoxon U-test, for comparing XPA and vimentin (VIM)
knockdowns; and P¼ 0.07, using a Wilcoxon U-test, when
comparing double knockdown to vimentin knockdown). These
results argue that neither MSH2 nor XPA are involved in
generating contractions at Cas9 nickase-induced lesions.
We reasoned that ATR inhibition may be increasing the
number of expansions and contractions because DSB intermedi-
ates may form under these conditions. We therefore tested
whether the NER pathway, which is known to generate DSBs on
ultraviolet damage45 and at short inverted repeats46, could
contribute to repeat instability in the absence of ATR activity.
Knockdown of XPA in cells treated with VE-821 led to results
indistinguishable from those obtained when treating cells with
DMSO together with a control siRNA (Fig. 4c, P¼ 0.70, using a
Wilcoxon U-test). Similarly, the effect of VE-821 treatment was
suppressed by MSH2 knockdown (Fig. 4c, P¼ 0.71 compared
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Figure 4 | Mechanism of Cas9-nickase-induced repeat instability. (a) Quantiﬁcation of GFP and GFPþ cells on treatment with DMSO (n¼ 20, which
includes the amount of DMSO for treatment with one or two inhibitors in GFP(CAG)101 cells; these controls were indistinguishable from each other), an
ATR inhibitor (VE-821, n¼ 5), or an ATM inhibitor (KU60019, n¼ 5), or both (n¼ 3). Dashed line: dimmest (GFP) or brightest (GFPþ) 1% of the cells
transfected with the Cas9 nickase vector together with the empty gRNA plasmid and treated with the DMSO or the indicated inhibitor. (b) Quantiﬁcation of
the GFP and GFPþ cells on knockdown with siRNAs (siVIM, n¼ 13; siMSH2, n¼ 14; siXPA, n¼9; siMSH2þ siXPA, n¼4). siVIM quantiﬁcations include
results from knockdown of vimentin with both 10 and 20 nM of siRNAs as the results were indistinguishable from each other. Dashed line: dimmest
(GFP) or brightest (GFPþ) 1% of the cells transfected with the Cas9 nickase vector; the empty gRNA plasmid; and the indicated siRNAs. (c)
Quantiﬁcation of the GFP and GFPþ cells on combinatorial knockdown of the indicated siRNAs and the ATR inhibitor VE-821 (siVIMþDMSO, n¼ 6;
siMSH2þATRi, n¼ 3; siXPAþATRi, n¼ 6). Dashed line: dimmest (GFP) or brightest (GFPþ) 1% of the cells transfected with the Cas9 nickase vector
together with the empty gRNA plasmid, and treated with the indicated inhibitors and siRNAs The error bars are s.e.m. *Pr0.05.
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with control DMSO and vimentin siRNA treatments, using a
Wilcoxon U-test). These results suggest that expansions and
contractions induced by the inhibition of ATR occur because of a
XPA- and MSH2-dependent activity that may eventually
generates DSBs.
Discussion
Many assays have been used with great success to dissect the
mechanisms of repeat instability. Unfortunately, they are often
slow, labour-intensive and/or cannot probe both expansions and
contractions at once15,24,33,47–49. Here we have adapted a
chromosomal-based reporter assay such that it can monitor
instability in both directions within only 5 days. We show that the
assay can be coupled to pharmaceutical treatments, siRNAs and
cDNA overexpression, making it highly versatile and well suited
for screening.
DNA nicks appear to be repaired by distinct and still poorly
understood mechanisms. For example, they stimulate homology-
directed repair in a human cell-based assay50. Intriguingly, this
process is suppressed by RAD51 and BRCA2, which are required
for homologous recombination at DSBs50. PARP inhibition
also stimulates nick-induced homology-directed repair51. Our
observation that the same PARP inhibitor has no effect on
nickase-induced contraction is suggestive of a different pathway
being used at CAG repeats and that DNA nicks are not the
mutagenic intermediates leading to nickase-induced contractions.
Furthermore, the lack of an effect when knocking down XRCC1
or inhibiting PARP1 implies that the Cas9 nickase leads to
contraction via a pathway different from that of BER-generated
SSBs. We cannot rule out that DNA nicks lead to contractions
independently of the known pathways leading to spontaneous
instability. Instead, however, we offer a model (Fig. 5) whereby
the Cas9 nickase induces several nicks on the same strand within
the repeat tract, thereby generating DNA gaps. This hypothesis is
attractive because it provides an explanation for the repeat-length
dependency of nickase-induced contractions: shorter repeats have
fewer gCTG-binding sites and thus DNA gaps are not created as
readily, leading to a stable tract. Together, these observations
suggest that different types of DNA lesions found within the
repeat tract are repaired by different pathways, which may dictate
the direction of repeat instability.
DNA gaps are important intermediates in CAG repeat
instability in model systems as varied as yeast and mice52–54.
How they lead to contraction, however, has remained unclear. In
our model (Fig. 5), we propose that DNA gaps caused by the Cas9
nickase are converted to contractions via an ATM-dependent
mechanism—perhaps by promoting ligation of single-stranded
DNA ends across a hairpin. This intermediate could be further
processed or simply replicated in the following cell cycle to create
a contraction. DNA gap ﬁlling, promoted by ATR, would prevent
the involvement of ATM, providing an explanation for the
apparent role of ATR in antagonizing ATM. When ATR
signalling is compromised, an intermediate, possibly stabilized
by MSH2 (ref. 55) and/or XPA56, lingers and is processed more
often by an XPA-dependent recruitment of downstream
nucleases. The resulting DSB is further repaired via the same
error-prone pathway that processes ZFN and Cas9-induced DSBs.
The yeast homologue of ATR, Mec1, prevents the appearance
of contractions, most likely by preventing DSB formation at
expanded CAG repeats21. Tel1, the ATM homologue, had no
effect on CAG repeat instability14. Admittedly, budding yeast
displays a bias towards contractions in wild-type cells and may
therefore process CAG repeats differently than human cells.
Nevertheless, it is unclear why the roles that we have uncovered
here should be different than the ones uncovered in yeast. One
possibility is that the mutagenic intermediates that Mec1 and Tel1
are sensing in the yeast studies were different than those involved
here.
ATR and ATM heterozygosities also have distinct effects on the
instability of CGG/CCG repeats in mice. In agreement with data
presented here, ATR prevents the expansion of CGG/CCG
repeats both in somatic tissues as well as in non-replicating
prophase I-arrested mouse oocytes57. The effect of ATR on
contractions was not reported. Atmþ / animals, by contrast, did
not display an overt somatic instability phenotype. Instead, they
showed markedly increased frequencies of expansions in the male
germlines58. The effect on contractions was not reported. The
reason for these differences is currently unclear but may include
the very different nature of the trinucleotide repeats studied
(CAG/CTG versus CGG/CCG), and/or the difference between the
human cells used here and the in vivo mouse model used in both
previous studies. More work is required to resolve this issue.
Our results have profound implications for somatic gene
editing of expanded CAG diseases. Programmable nucleases were
proposed to provide a tool to shorten repeat tracts and a much
needed cure59. Some attempts have been made to test this
hypothesis using ZFNs or TALENs24,26,60,61. Our data caution
that inducing DSBs within the repeat tract in an attempt to shrink
them would also lead to repeat expansion. This would be a
problem because the expansions are likely to exacerbate the
disease phenotype22,23. An alternative may be to induce two DSBs
in regions immediately ﬂanking, but not within, the repeat tract.
This approach would be prone to off target effects62–64, may lead
to the mutation of the wild-type allele, and gRNAs would have to
be designed and tested for each disease locus. Our approach
would be simpler, using a single gRNA that could target any of
the disease loci. In addition, our data argue that only longer,
pathogenic, repeat tracts are targeted for contractions; an ideal
scenario as it leaves the normal allele intact.
For CAG repeat contraction to be a viable therapeutic avenue,
the disease phenotypes must be reversible. There is some evidence
that this is the case. Indeed, the myotonia and cardiac symptoms
of a myotonic dystrophy mouse model were reversible on
shutting off the expression of the pathogenic transgene65.
Similarly, halting the expression of a spinocerebellar ataxia type
1 allele with 82 CAGs markedly improved the pathological
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Figure 5 | Model for Cas9-nickase-induced repeat contraction.
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phenotype of Purkinje cells and reversed motor dysfunction66.
Homology-directed replacement of an expanded CAG repeat in
induced pluripotent stem cells (iPSC) derived from Huntington
disease patients improved suceptibility to cell death and
mitochondrial defects67. Removing a CGG/CCG repeat tract
along with ﬂanking sequences from the FMR1 gene with CRISPR-
Cas9 nuclease reactivated the expression of FMRP in a few iPSC
clones68. Finally, excising expanded GAA/TTC repeats in
Friedreich Ataxia ﬁbroblasts reactivated the expression of
frataxin, improved the activity of the Fe-S-containing Aconitase,
and increased cellular ATP levels69. Together with our results,
these studies offer great hope that Cas9 nickase-mediated
shrinkage of expanded repeat tracts in somatic tissues may
alleviate disease symptoms in patients.
Methods
Cell culture. The GFP(CAG)0 and GFP(CAG)101 cells lines were a kind gift from
John H. Wilson24. The cells tested negative for mycoplasma using the MycoAlert
detection kit (Lonza) at the start of our experiments and during the revisions of this
manuscript. The GFP(CAG)15, GFP(CAG)18, GFP(CAG)42, GFP(CAG)50 and
GFP(CAG)270 were isolated from populations grown for 6 months unperturbed or
after transfection with the ZFN. They did not contain mutations in the region
ﬂanking the repeat tract. The cells were maintained at 37 C with 5% CO2 in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) glutamax, supplemented with 10%
fetal bovine serum (FBS), 100Uml 1 penicillin (pen), 100 mgml 1 streptomycin
(strep), 15mgml 1 blasticidine and 150mgml 1 hygromycin. When the cells were
destined for ﬂow cytometry, they were kept in DMEM glutamax, with 10% of
dialysed calf serum, along with pen–strep. During the long-term culturing, the
unstransfected and unperturbed cells were split one to ﬁve twice a week, and the
medium was supplemented with blasticidine and hygromycin to ensure continued
expression of the TetR and GFP transgenes.
Plasmids and siRNA transfections. The plasmids used in this study are found in
Supplementary Table 4. They are available on request. cDNA transfections were
performed using 6 105 cells per well in 12-well plates using a total of 1 mg of DNA
and Lipofectamine 2000 (Life Technologies) per well. The culture medium was
replaced 6 h after transfection and 2 mgml 1 of dox, diluted in DMSO, was added.
Controls without dox were treated with DMSO alone. Forty-eight hours later, the
medium was replaced and dox was freshly added. Flow cytometry, protein
extraction and/or DNA extraction were performed after another 48 h of incubation.
The siRNAs used in this study are found in Supplementary Table 5. When
transfecting with both a cDNA and a siRNA, 8 105 cells per well were used along
with 1 mg of DNA and 20 nM of siRNAs using Lipofectamine 2000. The medium
was replaced 6 h later and dox was added. Forty-eight hours after the ﬁrst
transfection, we performed a second siRNA transfection with RNAiMax (Life
Technologies) using half of the cells present and 20 nM of siRNA. We collected the
cells to assess knockdown efﬁciency or GFP ﬂuorescence analysis 48 h later. When
transfecting two siRNAs, we used a ﬁnal siRNA concentration of 40 nM, where
20 nM of each individual siRNA were used. We found that single knockdowns at
20 nM were no different from those also containing 20 nM of the vimentin siRNA
and were pooled for the statistical analyses and in the presented ﬁgures.
Pharmacological inhibitors. When using small-molecule inhibitors
(Supplementary Table 6), the cells were treated as above. The medium, along with
the dox and the inhibitors, was replaced after 48 h and for another 48 h of treat-
ment. Cell cycle analysis was performed after 96 h of treatment. Brieﬂy, the cells
were ﬁxed with 100% ethanol and treated with RNAseA (50 mgml 1) before
adding propidium iodine (50 mgml 1). Flow cytometry analysis was performed as
described below.
Flow cytometer and cell sorting. In preparation for ﬂow cytometry analysis, cells
were re-suspended in phosphate-buffered saline (PBS) with 1mM EDTA to a
concentration of about 106 cells per ml. For each condition, we measured at least
2 105 events using a LSRII from BD. Data analysis was done using Flowing II.
FACS was performed using a FACS Aria II (BD) or MoFlo Astrios (Beckman
Coulter). For single-clone analyses, we re-suspended the cells to a concentration of
2 106 cells per ml and sorted the GFP and GFPþ cells. The cells were then
expanded in DMEM glutamax supplemented with pen–strep, blasticidine, hygro-
mycin, 5% FBS and 5% dialysed calf serum. For viability tests, cells were treated as
described above except that 96 h after the ﬁrst transfection they were collected in
PBS with 1mM EDTA, and 1 mM of TO-PRO-3 was added as a dead cell marker.
Quantiﬁcation of GFP and GFPþ cells. To quantify the fold increase in the
number of GFP or GFPþ cells, we ﬁrst established gates that contained the top
or bottom 1% of GFP-expressing cells in the control treatment, for example, the
nickase plasmid transfected together with an empty gRNA vector (pPN10). For
each treatment or cell line, therefore, the top and bottom 1% were adjusted to take
any shift in GFP expression into account. In some cases, we adjusted the voltage of
the ﬂow cytometer laser to accommodate samples with very high or very low GFP
expression. This adjustment did not interfere with the quantiﬁcation
(Supplementary Fig. 3C,D). Once the GFP gates were established, we calculated the
percentage of cells from the test population (for example, expressing both the Cas9
nickase and the gCTG) falling within these same gates. In cases where inhibitors or
siRNAs were used, the control population expressed the Cas9 nickase, pPN10 and
the inhibitor or siRNA. The 1% cutoffs were used to keep a balance between having
enough cells for robust statistics and detecting signiﬁcant fold changes24. This
method probably underestimates the frequencies of change compared with SP-PCR
(Fig. 2).
Repeat length determination and SP-PCR. To determine the repeat length of
each sorted clone, we isolated DNA using the PeqGold MicroSpin Tissue DNA kit
(PeqLab). The DNA was then ampliﬁed with primers oVIN-0437 and oVIN-0459
(Supplementary Table 7). Several PCR reactions were set-up with MangoTaq and
the products were gel-extracted, pooled and sent for sequencing with the same
primers used for the ampliﬁcation. The repeat size was determined from at least
two different ampliﬁcation and sequencing reactions. The longest repeat size
determined was used in the rare cases where the repeat length was not identical
between the runs. SP-PCR was done based on the protocol described in ref. 70.
Brieﬂy, primers oVIN-0459 and oVIN-0460 were used for the ampliﬁcation along
with between 50 and 100 pg of genomic DNA per PCR. The products were then
run on an agarose gel and transferred into a membrane. The probe was derived
from a PCR product ampliﬁed with the same primers from a plasmid containing 40
repeats. The primers used to amplify the off-target loci are found in Supplementary
Table 7.
Antibodies and western blotting. Protein extraction was done using RIPA buffer
and proteinase inhibitor cocktail tablets (Roche, Germany) and at least 10 mg of
proteins were loaded onto 6 or 10% Tris/glycine SDS polyacrylamide gels and
transferred onto nitrocellulose membranes. The antibodies used in this study are
found in Supplementary Table 8. An Odyssey Infrared Imager (Licor) was used for
signal detection. All uncropped western blots are found in Supplementary Fig. 5.
Statistics. When determining whether there were differences in the frequency of
GFP and GFPþ cells between treatments, we were unable to guarantee that the
data were normally distributed using a two-tailed Kolmogorov–Smirnov test.
We therefore used a two-tailed Wilcoxon U-test as it is non-parametric. We also
performed two-tailed Student’s t-tests, which gave similar results as the U-tests.
The same was true when comparing length of the repeat tracts in clones sorted
from different populations. We used a Poisson distribution to evaluate the total
number of alleles ampliﬁed in our SP-PCR experiments based on the proportion of
PCRs that did not yield a detectable product. Fisher’s exact tests were used to
determine whether there were changes in the number of contractions and
expansions seen in the SP-PCR experiment. All statistical analyses were done using
R Studio version 0.99.441. We concluded that a signiﬁcant difference existed when
Po0.05.
Data availability. The data presented in this study are available from the
corresponding author.
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